8-K: Bionano Genomics Enters $75 Million At-The-Market Offering Agreement with H.C. Wainwright

Bionano Genomics has entered into an agreement with H.C. Wainwright & Co. to sell up to $75 million of its common stock through an at-the-market offering.

Summary

• Bionano Genomics has entered into an At The Market (ATM) Offering Agreement with H.C. Wainwright & Co. on February 21, 2025.
• Under the agreement, Bionano may offer and sell shares of its common stock, from time to time, up to an aggregate offering price of $75.0 million.
• The shares will be sold through or to Wainwright, acting as sales agent or principal.
• Sales will be made pursuant to the company's shelf registration statement on Form S-3, effective May 10, 2023, and a related prospectus supplement filed on February 21, 2025.
• Bionano is not obligated to sell any shares under the ATM Agreement.
• The company will notify Wainwright each time it wishes to issue and sell shares, specifying the number of shares, dates of sale, limitations on the number of shares sold per day, and any minimum price requirements.
• Wainwright will use commercially reasonable efforts to sell the shares, subject to the terms and conditions of the agreement.
• Wainwright may sell shares through the Nasdaq Capital Market, other trading markets, or in privately negotiated transactions.
• Bionano will pay Wainwright a commission equal to 3.0% of the aggregate gross proceeds from each sale of shares, reimburse certain legal fees, and provide customary indemnification.
• The ATM Agreement can be terminated by Bionano with five business days' notice or by Wainwright at any time.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The announcement is a standard financial procedure (ATM offering). While it provides financial flexibility, it also carries the risk of dilution. The sentiment is therefore moderately positive.

Positives

• The ATM offering provides Bionano Genomics with flexibility in raising capital.
• The company is not obligated to sell any shares, allowing it to time sales strategically.
• The agreement allows for sales through various methods, including direct market sales and privately negotiated transactions.

Negatives

• The offering could dilute existing shareholders' equity.
• The company will incur commissions and legal fees associated with the offering, reducing the net proceeds.
• There is no guarantee that the company will be able to sell all $75 million worth of shares.

Risks

• Market conditions may not be favorable for selling shares at desired prices.
• The offering could negatively impact the company's stock price.
• Failure to effectively deploy the raised capital could impact future growth.

Future Outlook

Bionano Genomics intends to use the net proceeds from the ATM offering for general corporate purposes, but specific details are not provided in this document.

Industry Context

ATM offerings are a common method for companies, particularly in the biotech sector, to raise capital opportunistically. This allows them to take advantage of favorable market conditions without the commitment of a traditional underwritten offering.

Comparison to Industry Standards

• Comparable companies in the biotech industry, such as Pacific Biosciences or Oxford Nanopore Technologies, have also utilized ATM offerings to raise capital.
• The commission rate of 3.0% is within the typical range for ATM offerings.
• The size of the offering, $75 million, is relatively modest compared to some larger capital raises in the sector, but appropriate for a company of Bionano's size and market capitalization.

Stakeholder Impact

• Shareholders may experience dilution of their ownership.
• The company may have additional capital to fund operations and growth.
• Employees may benefit from the company's improved financial position.

Next Steps

• Bionano Genomics will decide when and how many shares to offer under the ATM agreement.
• H.C. Wainwright & Co. will attempt to sell the shares according to the terms of the agreement.
• The company will file necessary reports with the SEC regarding the offering.

Key Dates